POTENTIAL TARGETS FROM HUMAN (RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES)
1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		1bey CAMPATH-1H ANTIBODY
(Homo
sapiens)		5 / 12THR H  89
VAL H 119
VAL H 117
VAL H  70
TYR H  96
None
1.27A18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		1bvl HULYS11
(Homo
sapiens;
Mus
musculus)		5 / 12THR A  86
VAL A 114
VAL A 112
VAL A  67
TYR A  93
None
1.47A15.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		2zkj [PYRUVATE
DEHYDROGENASE
[LIPOAMIDE]] KINASE
ISOZYME 4
(Homo
sapiens)		5 / 12THR A  82
VAL A  85
VAL A  88
ASP A 143
PHE A 162
None
1.21A21.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		3d3l ARACHIDONATE
12-LIPOXYGENASE,
12S-TYPE
(Homo
sapiens)		5 / 12VAL A 367
ASP A 512
PHE A 515
PHE A 528
VAL A 517
None
1.28A22.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		3lpp SUCRASE-ISOMALTASE
(Homo
sapiens)		5 / 12TRP A 453
THR A 537
VAL A 541
VAL A 544
ASP A 472
None
None
None
None
TRS  A6001 (-3.2A)
1.19A17.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		3pbl D(3) DOPAMINE
RECEPTOR, LYSOZYME
CHIMERA
(Homo
sapiens;
Escherichia
virus
T4)		5 / 12VAL A 111
TRP A 342
PHE A 345
PHE A 346
TYR A 373
ETQ  A1200 (-3.4A)
None
ETQ  A1200 (-4.4A)
ETQ  A1200 ( 4.5A)
ETQ  A1200 (-4.4A)
0.51A27.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Homo
sapiens;
Escherichia
virus
T4)		10 / 12TRP A 109
THR A 110
VAL A 114
VAL A 117
ASP A 192
PHE A 193
TRP A 286
PHE A 289
PHE A 290
TYR A 316
None
ERC  A1201 ( 4.6A)
ERC  A1201 (-3.8A)
None
ERC  A1201 (-4.2A)
ERC  A1201 (-4.4A)
None
ERC  A1201 (-4.5A)
ERC  A1201 (-4.8A)
None
0.84A37.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Homo
sapiens;
Escherichia
virus
T4)		10 / 12TRP A 109
THR A 110
VAL A 114
VAL A 117
ASP A 192
TRP A 286
PHE A 289
PHE A 290
ASN A 293
TYR A 316
None
ERC  A1201 ( 4.6A)
ERC  A1201 (-3.8A)
None
ERC  A1201 (-4.2A)
None
ERC  A1201 (-4.5A)
ERC  A1201 (-4.8A)
ERC  A1201 (-3.5A)
None
0.77A37.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4gbr BETA-2 ADRENERGIC
RECEPTOR
(Homo
sapiens)		10 / 12TRP A 109
THR A 110
VAL A 114
VAL A 117
ASP A 192
PHE A 193
TRP A 258
PHE A 261
PHE A 262
TYR A 288
None
CAU  A 500 ( 4.0A)
CAU  A 500 (-3.5A)
CAU  A 500 (-4.2A)
None
CAU  A 500 (-4.5A)
None
CAU  A 500 (-4.2A)
CAU  A 500 (-4.6A)
CAU  A 500 (-4.6A)
0.72A50.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4gbr BETA-2 ADRENERGIC
RECEPTOR
(Homo
sapiens)		10 / 12TRP A 109
THR A 110
VAL A 114
VAL A 117
ASP A 192
TRP A 258
PHE A 261
PHE A 262
ASN A 265
TYR A 288
None
CAU  A 500 ( 4.0A)
CAU  A 500 (-3.5A)
CAU  A 500 (-4.2A)
None
None
CAU  A 500 (-4.2A)
CAU  A 500 (-4.6A)
CAU  A 500 (-3.4A)
CAU  A 500 (-4.6A)
0.71A50.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4ib4 CHIMERA PROTEIN OF
HUMAN
5-HYDROXYTRYPTAMINE
RECEPTOR 2B AND E.
COLI SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		7 / 12TRP A 131
VAL A 136
TRP A 337
PHE A 340
PHE A 341
ASN A 344
TYR A 370
None
ERM  A2001 (-3.8A)
None
ERM  A2001 (-4.3A)
None
ERM  A2001 (-4.3A)
ERM  A2001 ( 4.8A)
0.47A26.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Homo
sapiens;
Escherichia
virus
T4)		11 / 12TRP A1109
THR A1110
VAL A1114
VAL A1117
ASP A1192
PHE A1193
TRP A1286
PHE A1289
PHE A1290
ASN A1293
TYR A1316
None
P0G  A1401 ( 3.9A)
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.4A)
None
P0G  A1401 (-3.8A)
None
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-3.0A)
None
0.44A45.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4ni2 GUANYLATE CYCLASE
SOLUBLE SUBUNIT
BETA-1
(Homo
sapiens)		5 / 12VAL B 482
VAL B 472
ASP B 418
VAL B 529
TYR B 540
None
EDO  B 701 ( 4.9A)
None
None
None
1.48A16.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4xmp HEAVY CHAIN OF
ANTIBODY VRC08
(Homo
sapiens)		5 / 12THR H  83
VAL H 111
VAL H 109
VAL H  67
TYR H  90
None
1.29A18.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5d1q D2-06 HEAVY CHAIN
(Homo
sapiens)		5 / 12THR B  83
VAL B 111
VAL B 109
VAL B  67
TYR B  90
None
1.36A19.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5d1z D4-10 HEAVY CHAIN
(Homo
sapiens)		5 / 12THR D  88
VAL D 126
VAL D 124
VAL D  69
TYR D  95
None
1.36A19.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5iaa UBIQUITIN-LIKE
MODIFIER-ACTIVATING
ENZYME 5
(Homo
sapiens)		5 / 12VAL A 175
VAL A 178
PHE A 103
PHE A 160
VAL A 146
None
1.33A21.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5ljy SCFVA5
(Homo
sapiens)		5 / 12THR H  83
VAL H 111
VAL H 109
VAL H  67
TYR H  90
None
1.44A18.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5v54 5-HYDROXYTRYPTAMINE
RECEPTOR 1B,OB-1
FUSED 5-HT1B
RECEPTOR,5-HYDROXYTR
YPTAMINE RECEPTOR 1B
(Spodoptera
frugiperda;
Homo
sapiens)		5 / 12TRP A 125
TRP A 327
PHE A 330
PHE A 331
TYR A 359
None
89F  A1201 (-3.6A)
89F  A1201 (-4.1A)
89F  A1201 (-4.6A)
None
0.60Aundetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5wde KINESIN-LIKE PROTEIN
KIFC3
(Homo
sapiens)		5 / 12VAL A 452
VAL A 745
ASP A 472
PHE A 471
ASN A 467
None
None
UNX  A 909 ( 3.7A)
None
None
1.45A20.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens)		5 / 12VAL A 116
TRP A 407
PHE A 410
PHE A 411
TYR A 438
AQD  A1201 ( 3.9A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
0.53A30.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens)		5 / 12VAL A 116
TRP A 407
PHE A 410
PHE A 411
VAL A 430
AQD  A1201 ( 3.9A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
1.26A30.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		6 / 12TRP A 130
TRP A 324
PHE A 327
PHE A 328
ASN A 331
TYR A 358
None
E2J  A1201 ( 3.7A)
E2J  A1201 (-4.6A)
E2J  A1201 (-4.4A)
None
None
0.56Aundetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		6 / 12TRP A 130
VAL A 135
TRP A 324
PHE A 327
PHE A 328
TYR A 358
None
E2J  A1201 (-3.8A)
E2J  A1201 ( 3.7A)
E2J  A1201 (-4.6A)
E2J  A1201 (-4.4A)
None
0.63Aundetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		6cm4 D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA
(Homo
sapiens;
Escherichia
virus
T4)		5 / 12VAL A 115
TRP A 386
PHE A 389
PHE A 390
TYR A 416
8NU  A2001 ( 3.5A)
8NU  A2001 ( 3.8A)
8NU  A2001 ( 4.5A)
8NU  A2001 ( 4.8A)
8NU  A2001 ( 4.9A)
0.60A25.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		6g79 5-HYDROXYTRYPTAMINE
RECEPTOR 1B
(Homo
sapiens)		5 / 12TRP S 125
TRP S 327
PHE S 330
PHE S 331
TYR S 359
None
None
EP5  S 401 (-4.0A)
EP5  S 401 (-4.7A)
EP5  S 401 ( 4.9A)
0.51Aundetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_1
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Homo
sapiens;
Escherichia
virus
T4)		4 / 4ASP A 113
SER A 203
SER A 207
ASN A 312
ERC  A1201 (-3.7A)
ERC  A1201 (-2.8A)
ERC  A1201 (-2.7A)
ERC  A1201 (-3.0A)
0.65A37.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_1
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Homo
sapiens;
Escherichia
virus
T4)		4 / 4ASP A1113
SER A1203
SER A1207
ASN A1312
P0G  A1401 (-2.9A)
P0G  A1401 (-2.9A)
P0G  A1401 (-2.8A)
P0G  A1401 (-2.9A)
0.20A45.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_A_H98A501_1
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Homo
sapiens;
Escherichia
virus
T4)		4 / 4ASP A1113
SER A1204
SER A1207
ASN A1312
P0G  A1401 (-2.9A)
P0G  A1401 ( 3.7A)
P0G  A1401 (-2.8A)
P0G  A1401 (-2.9A)
1.11A45.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_1
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5gs2 ANTI-REPEBODY
ANTI-MBP
(Mus
musculus;
Homo
sapiens)		4 / 4ASP H 133
SER H 127
SER H 126
ASN D  61
None
1.41A21.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_A_H98A501_1
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		6aqf ADENOSINE RECEPTOR
A2A,SOLUBLE
CYTOCHROME
B562,ADENOSINE
RECEPTOR A2A
(Escherichia
coli;
Homo
sapiens)		4 / 4ASP A  52
SER A  90
SER A  94
ASN A 280
None
1.46Aundetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		1bey CAMPATH-1H ANTIBODY
(Homo
sapiens)		5 / 12THR H  89
VAL H 119
VAL H 117
VAL H  70
TYR H  96
None
1.28A18.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		1bvl HULYS11
(Homo
sapiens;
Mus
musculus)		5 / 12THR A  86
VAL A 114
VAL A 112
VAL A  67
TYR A  93
None
1.48A15.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		2zkj [PYRUVATE
DEHYDROGENASE
[LIPOAMIDE]] KINASE
ISOZYME 4
(Homo
sapiens)		5 / 12THR A  82
VAL A  85
VAL A  88
ASP A 143
PHE A 162
None
1.21A21.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		3d3l ARACHIDONATE
12-LIPOXYGENASE,
12S-TYPE
(Homo
sapiens)		5 / 12VAL A 367
ASP A 512
PHE A 515
PHE A 528
VAL A 517
None
1.25A22.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		3pbl D(3) DOPAMINE
RECEPTOR, LYSOZYME
CHIMERA
(Homo
sapiens;
Escherichia
virus
T4)		5 / 12VAL A 111
TRP A 342
PHE A 345
PHE A 346
TYR A 373
ETQ  A1200 (-3.4A)
None
ETQ  A1200 (-4.4A)
ETQ  A1200 ( 4.5A)
ETQ  A1200 (-4.4A)
0.53A27.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Homo
sapiens;
Escherichia
virus
T4)		10 / 12TRP A 109
THR A 110
VAL A 114
ASP A 192
PHE A 193
TRP A 286
PHE A 289
PHE A 290
ASN A 293
TYR A 316
None
ERC  A1201 ( 4.6A)
ERC  A1201 (-3.8A)
ERC  A1201 (-4.2A)
ERC  A1201 (-4.4A)
None
ERC  A1201 (-4.5A)
ERC  A1201 (-4.8A)
ERC  A1201 (-3.5A)
None
0.80A37.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Homo
sapiens;
Escherichia
virus
T4)		10 / 12TRP A 109
THR A 110
VAL A 114
VAL A 117
ASP A 192
PHE A 193
TRP A 286
PHE A 289
PHE A 290
ASN A 293
None
ERC  A1201 ( 4.6A)
ERC  A1201 (-3.8A)
None
ERC  A1201 (-4.2A)
ERC  A1201 (-4.4A)
None
ERC  A1201 (-4.5A)
ERC  A1201 (-4.8A)
ERC  A1201 (-3.5A)
0.79A37.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4gbr BETA-2 ADRENERGIC
RECEPTOR
(Homo
sapiens)		11 / 12TRP A 109
THR A 110
VAL A 114
VAL A 117
ASP A 192
PHE A 193
TRP A 258
PHE A 261
PHE A 262
ASN A 265
TYR A 288
None
CAU  A 500 ( 4.0A)
CAU  A 500 (-3.5A)
CAU  A 500 (-4.2A)
None
CAU  A 500 (-4.5A)
None
CAU  A 500 (-4.2A)
CAU  A 500 (-4.6A)
CAU  A 500 (-3.4A)
CAU  A 500 (-4.6A)
0.80A50.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4ib4 CHIMERA PROTEIN OF
HUMAN
5-HYDROXYTRYPTAMINE
RECEPTOR 2B AND E.
COLI SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		7 / 12TRP A 131
VAL A 136
TRP A 337
PHE A 340
PHE A 341
ASN A 344
TYR A 370
None
ERM  A2001 (-3.8A)
None
ERM  A2001 (-4.3A)
None
ERM  A2001 (-4.3A)
ERM  A2001 ( 4.8A)
0.48A26.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Homo
sapiens;
Escherichia
virus
T4)		11 / 12TRP A1109
THR A1110
VAL A1114
VAL A1117
ASP A1192
PHE A1193
TRP A1286
PHE A1289
PHE A1290
ASN A1293
TYR A1316
None
P0G  A1401 ( 3.9A)
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.4A)
None
P0G  A1401 (-3.8A)
None
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-3.0A)
None
0.39A45.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4ni2 GUANYLATE CYCLASE
SOLUBLE SUBUNIT
BETA-1
(Homo
sapiens)		5 / 12VAL B 482
VAL B 472
ASP B 418
VAL B 529
TYR B 540
None
EDO  B 701 ( 4.9A)
None
None
None
1.45A16.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4xmp HEAVY CHAIN OF
ANTIBODY VRC08
(Homo
sapiens)		5 / 12THR H  83
VAL H 111
VAL H 109
VAL H  67
TYR H  90
None
1.30A18.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4xny HEAVY CHAIN OF
ANTIBODY VRC08C
(Homo
sapiens)		5 / 12THR H  83
VAL H 111
VAL H 109
VAL H  67
TYR H  90
None
1.32A19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5d1q D2-06 HEAVY CHAIN
(Homo
sapiens)		5 / 12THR B  83
VAL B 111
VAL B 109
VAL B  67
TYR B  90
None
1.36A19.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5iaa UBIQUITIN-LIKE
MODIFIER-ACTIVATING
ENZYME 5
(Homo
sapiens)		5 / 12VAL A 175
VAL A 178
PHE A 103
PHE A 160
VAL A 146
None
1.31A21.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5ljy SCFVA5
(Homo
sapiens)		5 / 12THR H  83
VAL H 111
VAL H 109
VAL H  67
TYR H  90
None
1.45A18.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5u0u DH270.1 SINGLE-CHAIN
VARIABLE FRAGMENT
(Homo
sapiens)		5 / 12THR G  87
VAL G 125
VAL G 123
VAL G  68
TYR G  94
None
1.35A18.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5v54 5-HYDROXYTRYPTAMINE
RECEPTOR 1B,OB-1
FUSED 5-HT1B
RECEPTOR,5-HYDROXYTR
YPTAMINE RECEPTOR 1B
(Spodoptera
frugiperda;
Homo
sapiens)		5 / 12TRP A 125
TRP A 327
PHE A 330
PHE A 331
TYR A 359
None
89F  A1201 (-3.6A)
89F  A1201 (-4.1A)
89F  A1201 (-4.6A)
None
0.62Aundetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5wde KINESIN-LIKE PROTEIN
KIFC3
(Homo
sapiens)		5 / 12VAL A 452
VAL A 745
ASP A 472
PHE A 471
ASN A 467
None
None
UNX  A 909 ( 3.7A)
None
None
1.36A20.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens)		5 / 12VAL A 116
TRP A 407
PHE A 410
PHE A 411
TYR A 438
AQD  A1201 ( 3.9A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
0.57A30.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens)		5 / 12VAL A 116
TRP A 407
PHE A 410
PHE A 411
VAL A 430
AQD  A1201 ( 3.9A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
1.28A30.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		6bp2 MR191 FAB HEAVY
CHAIN
(Homo
sapiens)		5 / 12THR H  88
VAL H 124
VAL H 122
VAL H  69
TYR H  95
None
1.42Aundetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		6 / 12TRP A 130
TRP A 324
PHE A 327
PHE A 328
ASN A 331
TYR A 358
None
E2J  A1201 ( 3.7A)
E2J  A1201 (-4.6A)
E2J  A1201 (-4.4A)
None
None
0.59Aundetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		6 / 12TRP A 130
VAL A 135
TRP A 324
PHE A 327
PHE A 328
TYR A 358
None
E2J  A1201 (-3.8A)
E2J  A1201 ( 3.7A)
E2J  A1201 (-4.6A)
E2J  A1201 (-4.4A)
None
0.61Aundetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		6cm4 D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA
(Homo
sapiens;
Escherichia
virus
T4)		5 / 12VAL A 115
TRP A 386
PHE A 389
PHE A 390
TYR A 416
8NU  A2001 ( 3.5A)
8NU  A2001 ( 3.8A)
8NU  A2001 ( 4.5A)
8NU  A2001 ( 4.8A)
8NU  A2001 ( 4.9A)
0.58A25.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_0
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		6g79 5-HYDROXYTRYPTAMINE
RECEPTOR 1B
(Homo
sapiens)		5 / 12TRP S 125
TRP S 327
PHE S 330
PHE S 331
TYR S 359
None
None
EP5  S 401 (-4.0A)
EP5  S 401 (-4.7A)
EP5  S 401 ( 4.9A)
0.55Aundetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_B_H98B501_1
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Homo
sapiens;
Escherichia
virus
T4)		4 / 4ASP A 113
SER A 203
SER A 207
ASN A 312
ERC  A1201 (-3.7A)
ERC  A1201 (-2.8A)
ERC  A1201 (-2.7A)
ERC  A1201 (-3.0A)
0.65A37.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_B_H98B501_1
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Homo
sapiens;
Escherichia
virus
T4)		4 / 4ASP A1113
SER A1203
SER A1207
ASN A1312
P0G  A1401 (-2.9A)
P0G  A1401 (-2.9A)
P0G  A1401 (-2.8A)
P0G  A1401 (-2.9A)
0.21A45.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6IBL_B_H98B501_1
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Homo
sapiens;
Escherichia
virus
T4)		4 / 4ASP A1113
SER A1204
SER A1207
ASN A1312
P0G  A1401 (-2.9A)
P0G  A1401 ( 3.7A)
P0G  A1401 (-2.8A)
P0G  A1401 (-2.9A)
1.08A45.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6IBL_B_H98B501_1
(THIOREDOXIN 1,BETA-1
ADRENERGIC RECEPTOR)		5gs2 ANTI-REPEBODY
ANTI-MBP
(Mus
musculus;
Homo
sapiens)		4 / 4ASP H 133
SER H 127
SER H 126
ASN D  61
None
1.37A21.76